Acumen pharmaceuticals to participate in the stifel healthcare conference

Charlottesville, va. and indianapolis, in., nov. 07, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the stifel healthcare conference on tuesday, nov. 14, 2023 at 2:25 p.m. et. the live webcast may be accessed under the investors tab on www.acumenpharm.com and will be archived for 90 days.
ABOS Ratings Summary
ABOS Quant Ranking